BIO Chart

1 Month

	Date	Diff
	2023-10-27	-7.15 %
Bio-Rad Laboratories (BIO) stock went down by 7.15% after the company lowered its revenue growth forecast, citing the uncertain recovery of the biopharma sector and macro challenges.
	2023-10-26	+0.5 %
Bio-Rad Laboratories (BIO) stock went up 0.5% after the company reported its third-quarter financial results, which showed a decrease in net sales compared to the previous year due to lower sales in the Life Science segment. The company also lowered its full-year 2023 outlook due to challenges in the biopharma sector and a challenging macroeconomic environment in China. Bio-Rad Laboratories' stock went down about 11% in extended trading after the company lowered its annual revenue growth forecast due to challenges in the biopharma sector and a difficult macroeconomic environment in China, reporting lower sales in its life science segment but higher sales in its clinical diagnostics unit.
	2023-10-23	-2.86 %
Bio-Rad Laboratories (BIO) stock went down by -2.86% due to concerns about the medium-term outlook for Sartorius, a pharma and laboratory equipment manufacturer, after it reduced its annual targets and experienced destocking following the end of the pandemic.
	2023-10-18	-7.93 %
The article announces the appointment of Ilan Daskal as the Executive Vice President and Chief Financial Officer of Viavi Solutions Inc., and does not provide information on why Bio-Rad Laboratories (BIO) stock went down.
	2023-09-20	+1.12 %
Bio-Rad Laboratories (BIO) stock went up 1.12% last night, despite it being a tough year for the healthcare sector, and Wall Street analysts like it because it has a Buy rating from four of the five analysts tracked by FactSet who cover the company.
	2023-09-14	+1.28 %
Bio-Rad Laboratories (BIO) stock went up by 1.28% after NRx Pharmaceuticals announced an agreement with LS Associates to provide financial services and support.
	2023-09-08	-2.71 %
Bio-Rad Laboratories' stock has seen a decline, possibly due to a valuation analysis that suggests the stock is undervalued, despite fair financial health and profitability, but a lower growth rate and lack of value creation for shareholders compared to industry peers.
	2023-08-29	+2.65 %
The article discusses the estimated fair value of Bio-Rad Laboratories (BIO) stock and concludes that the current share price suggests it is trading close to its fair value. The stock went up 2.65% last night, but the article does not provide an explanation for this increase.
	2023-08-28	+0.94 %
Bio-Rad Laboratories (BIO) stock went up 0.94% due to the announcement that the company's management will participate in a fireside chat event during Wells Fargo's 2023 Healthcare Conference.
	2023-08-14	-0.5 %
Bio-Rad Laboratories (BIO) stock went down by -0.5% last night, and the reason behind the decline is not mentioned in the article.
	2023-08-04	-0.45 %
The article discusses the stock performance of Bio-Rad Laboratories Inc (BIO) and examines its valuation. Despite a daily gain of 3.5%, the stock is considered significantly undervalued based on its GF Value estimate. The company's financials, including its cash-to-debt ratio and profitability, are deemed fair, but its growth rates rank lower than industry peers.
	2023-07-26	+0.51 %
Bio-Rad Laboratories (BIO) stock went up 0.51% after the company settled its patent dispute with QIAGEN N.V. and established a cross-licensing agreement relating to digital PCR technology.
	2023-07-20	+0.29 %
Bio-Rad Laboratories (BIO) stock went up by 0.29% after the company announced a new share repurchase program that allows them to buy back up to $500 million of outstanding shares of its common stock, showing its commitment to using this tool as part of its capital allocation strategy.
	2023-07-19	+3.24 %
Bio-Rad Laboratories (BIO) stock went up 3.24% last night due to investors fleeing healthcare stocks this year, as market conditions have changed and fear of a recession has eased, making healthcare stocks less attractive.
	2023-07-10	+0.87 %
Bio-Rad Laboratories' stock (BIO) went up by 0.87%, and the rise can potentially be attributed to the release of the company's corporate sustainability report, which highlights its progress towards achieving long-term sustainability goals. The article is a press release announcing that Bio-Rad Laboratories, a global leader in life science research and clinical diagnostic products, will be reporting its financial results for the second quarter of 2023 on August 3 and discussing them in a conference call. The reason for the uptick in Bio-Rad Laboratories' stock is not provided in the article.
	2023-06-26	-0.07 %
Bio-rad Laboratories (BIO) shares fell over 16% after reporting Q1 results that missed expectations, but Wells Fargo analyst Timothy Daley sees it as a buying opportunity, noting that investors underestimate the company’s long-term growth opportunity to enhance their earnings and margins, despite near-term sector and macro headwinds that are temporary in nature.
	2023-06-08	-3.51 %
The healthcare sector is performing well and has attracted billionaire investors looking for the defensive nature and adaptability of healthcare stocks, but Bio-Rad Laboratories Inc. (NYSE:BIO) stock went down by 3.51% due to mixed results reported in Q1 2023.